Nurtec ODT (rimegepant ODT) / Pfizer - LARVOL DELTA

Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. (PubMed, J Headache Pain) - "The study highlights the rapid uptake of rimegepant in Denmark, especially among middle-aged females with a history of triptan use and medication overuse. While rimegepant was associated with a reduction in acute medication overuse, early discontinuation rates suggest barriers to sustained use, potentially influenced by cost, efficacy, or patient preferences. There is a need for strategies to optimize long-term adherence and access to rimegepant in clinical practice."

Journal • CNS Disorders • Migraine • Pain

Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. (PubMed, Pain Manag) - "The NNT values for achieving pain freedom at two hours were 9 for rimegepant, 11 for zavegepant, and 12 for ubrogepant, which are comparable to NSAIDs such as naproxen (NNT = 11). Triptans demonstrated lower NNTs, indicating higher efficacy. Gepants offer effective, well-tolerated alternatives with no significant cardiovascular risk and minimal potential for medication-overuse headache."

Head-to-Head • Journal • Review • Cardiovascular • CNS Disorders • Migraine • Pain

Pfizer’s Nurtec approved in Korea, intensifying CGRP migraine treatment competition (Korea Biomedical Review) - "The Korean approval of Pfizer’s Nurtec, an oral calcitonin gene-related peptide (CGRP) targeting drug for both acute and preventive treatment, is expected to further intensify competition in the domestic migraine treatment market. According to the Ministry of Food and Drug Safety, Pfizer Korea's oral CGRP receptor antagonist, Nurtec Oral Disintegrating Tablets 75 mg (ingredient: rimegepant sulfate hydrate), was approved as a new drug on March 24....Beyond Nurtec, more migraine treatment options are expected to emerge in Korea. Lundbeck Korea aims to launch its CGRP monoclonal antibody eptinezumab (marketed as Vyepti internationally) in the first half of 2027."

Korea approval • Launch non-US • Migraine

Evaluating the Effect of Rimegepant Versus Oral Triptans Use on Patient-Reported Outcomes Among Adults with Migraine in the United States (P10-12.002). (PubMed, Neurology) - "Ms. Turko has received personal compensation for serving as an employee of Pfizer."

Clinical • Journal • CNS Disorders • Migraine • Pain

A Phase 4, Open-label Study Evaluating the Safety and Tolerability of Once Daily Rimegepant for Episodic Migraine Prevention (P11-4.008). (PubMed, Neurology) - "Dr. Fullerton has stock in Pfizer."

Journal • P4 data • CNS Disorders • Dyslipidemia • Hypertriglyceridemia • Infectious Disease • Migraine • Novel Coronavirus Disease • Pain

Interim Analysis of CONFIDENCE: A ProspeCtive ObservatioNal Study with Acute Treatment oF rImegepant ODT on ConsistENcy, SatisfaCtion and Tolerability of TrEatment in the Real World (P10-12.001). (PubMed, Neurology) - "Karin Hygge Blakeman has received personal compensation for serving as an employee of Pfizer. Karin Hygge Blakeman has stock in Pfizer."

Journal • Observational data • Real-world evidence • CNS Disorders • Migraine • Pain

New onset migraines after maxillary antrostomy for silent sinus syndrome treated with rimegepant: A rare case report. (PubMed, Braz J Otorhinolaryngol) - No abstract available

Journal • CNS Disorders • Migraine • Pain

CONFIDENCE: A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults. (clinicaltrials.gov) - P=N/A | N=342 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Mar 2025 | Trial primary completion date: Jun 2025 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Pain

Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol. (PubMed, Pain Manag) - "Chronic migraine is a disabling neurovascular disorder that represents the leading cause of years lived with disability in people under 50 with a remarkable social burden due to widespread resistance to the front-line treatments used routinely in current clinical practice. Furthermore, a feasible salivary biomarker of migraine is under investigation in the prospective stage of the study. Based on recent expert opinions supporting the switch to easy-to-use small molecule calcitonin gene-related peptide (CGRP)-targeting, i.e. rimegepant or atogepant in unresponsive patients, the present study may offer to clinicians a novel treatment to enhance the therapeutic preventive machinery in chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects (clinicaltrials.gov) - P3 | N=640 | Recruiting | Sponsor: Pfizer | Trial completion date: Apr 2027 ➔ Nov 2032 | Trial primary completion date: Apr 2027 ➔ Nov 2031

Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Pain • Pediatrics

Identification and characterization of unknown oxidation degradation products of Rimegepant by HPLC and triple quadrupole mass spectrometry. (PubMed, Eur J Mass Spectrom (Chichester)) - "Triple quadrupole mass spectrometry analysis characterized the five degradation products, which showed three N-oxide impurities with masses m/z 566, m/z 550, and m/z 548, as well as two hydrolysis products with masses, m/z 218, m/z 290. These new impurities deserve special attention because the drug's potency and related impurity levels determine any pharmaceutical medication product's quality, safety, and effectiveness."

Journal • CNS Disorders • Migraine • Pain

CORRELATE-UK: Consistency of Response With Rimegepant in Acute Treatment of Migraine (clinicaltrials.gov) - P=N/A | N=250 | Not yet recruiting | Sponsor: Pfizer

New trial • CNS Disorders • Migraine • Pain

Cost-effectiveness Analysis of Zavegepant in Acute Migraine Treatment (ISPOR 2025) - "Zavegepant is cost-effective compared with rimegepant for the acute treatment of migraine under the threshold of $100,000 per QALY gained."

Cost effectiveness • HEOR • CNS Disorders • Migraine • Pain

Comparative Risk of Major Adverse Cardiovascular Events among Patients who Initiate Treatment with Acute Migraine Agents (ISPOR 2025) - "Our study found that ubrogepant and rimegepant were associated with a lower risk of MACE compared to sumatriptan highlighting their potential as safer alternatives for patients with cardiovascular risk. No significant difference in MACE risk was observed between lasmiditan and sumatriptan suggesting the need for further research to better understand the cardiovascular safety profile of lasmiditan."

Adverse events • Clinical • Cardiovascular • CNS Disorders • Migraine • Myocardial Infarction • Pain

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine (clinicaltrials.gov) - P3 | N=723 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

UPLC-Q-TOF-MS/MS and NMR studies for the structural characterization of degradation impurities of rimegepant. (PubMed, Anal Bioanal Chem) - "A preparative HPLC was used to isolate the major degradation products for structural identification through 1D and 2D NMR studies. According to ICH Q2 (R1) guidelines, the developed UHPLC-PDA method was validated for its accuracy, precision, linearity, and specificity."

Journal • CNS Disorders • Migraine • Pain

Network Meta-Analysis Comparing Efficacy and Safety Outcomes of Atogepant, Rimegepant, and Galcanezumab in Patients with Episodic Migraine After Including CHALLENGE-MIG Trial (AAN 2025) - "Objective:Network meta-analysis (NMA) of atogepant (Ato) relative to rimegepant (Rime) and galcanezumab (Galc) after inclusion of the CHALLENGE-MIG trial for efficacy and safety outcomes in episodic migraine (EM) patients.Background:The NMA included 5 randomized, controlled trials for the preventive treatment of EM (ADVANCE [Ato 60 mg], BHV3000-305 [Rime 75 mg], EVOLVE-1, EVOLVE-2 [Galc 120 mg], and CHALLENGE-MIG [Rime 75 mg, Galc 120 mg]).Design/A fixed-effects model was chosen to compare the efficacy and safety of Ato versus Rime, Galc based on model fit statistics. Ato 60 mg demonstrated significant improvements in 3 of the 4 efficacy outcomes compared to Rime 75 mg and significantly increased odds of achieving ≥50% RR in MMD relative to Galc 120 mg. Other efficacy outcomes were not significantly different. Ato 60 mg demonstrated comparable all-cause d/c and TEAEs relative to Rime and Galc."

Retrospective data • CNS Disorders • Migraine • Pain

The Safety and Effectiveness of Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Migraine Treatment: A Focus on Small Molecule Antagonist and Ligand Monoclonal Combinations (AAN 2025) - "Our study aims to assess the effects of this dual-CGRP approach.Design/A retrospective matched cohort study was conducted at a neurological care center in Hawaii, analyzing 90 chronic migraine patients aged ≥18 years treated with CGRP inhibitors (L-mAbs: fremanezumab, galcanezumab, eptinezumab; SMAs: ubrogepant, rimegepant, atogepant; or a combination)...Variables included age, age at diagnosis, sex, onabotulinumtoxinA use, headache frequency, duration, severity, and associated symptoms before and three months post-treatment...Dual-CGRP regimens may provide improved effectiveness for controlling migraine symptoms by significantly reducing headache severity and aura symptoms without significant adverse events."

Clinical • CNS Disorders • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Efficacy and Safety of Rimegepant for the Prevention of Migraine in Japan (AAN 2025) - P3 | "RIM 75 mg EOD demonstrated efficacy superior to PBO for migraine prevention with a favorable safety profile. Funded by Pfizer."

Clinical • CNS Disorders • Migraine • Pain

Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mg (AAN 2025) - P2/3 | "Following rimegepant 75 mg treatment initiation, it is expected that half of patients will experience first and sustained 50% reductions in WMDs by week 2 and 3, respectively."

Clinical • CNS Disorders • Migraine • Pain

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japan (AAN 2025) - P3 | "RIM 75 mg demonstrated efficacy superior to PBO for the acute treatment of migraine, with a favorable safety profile, in participants in Japan. A dose-response relationship was observed for RIM."

Clinical • CNS Disorders • Migraine • Pain

Understanding Healthcare Providers' Perceptions and Prescribing Behaviors of Treatment for Short-Term Prevention of Migraine (AAN 2025) - "Rimegepant was most prescribed among gepant prescribers (94.4%); the primary driver for choice of gepant was indications for both acute and preventive treatment of migraine (62.7%). Findings suggest that HCPs believe patients with migraine, particularly those with perimenstrual migraine attacks, could benefit from the added control and flexibility of STP treatment. Further research is necessary to explore STP, which could enhance migraine care for patients."

CNS Disorders • Migraine • Pain

A Case Report of Calcitonin Gene-Related Peptide Antagonist as Treatment for Nummular Headache (AAN 2025) - "Non-steroidal anti-inflammatory drugs (NSAIDs), gabapentin, tricyclic antidepressants, and onabotulinum toxin A injections have been reported to be effective in small studies. This case highlights the CGRP antagonist medications as potential treatment options for severe or refractory nummular headache."

Case report • Clinical • CNS Disorders • Migraine • Pain

Sex Differences in Treatment Response and Patient Preference in Gepant Users: A Real-World Survey Study from a Tertiary Headache Center (AAN 2025) - "Gepant acute (rimegepant vs ubrogepant) and preventive (rimegepant vs atogepant) responses appear similar between sexes according to this real-world survey at a tertiary headache center. Further research is needed to understand the sex-based differences in gepant use response."

Clinical • Real-world • Real-world evidence • Pain

Interim Analysis of CONFIDENCE: A ProspeCtive ObservatioNal Study with Acute Treatment oF rImegepant ODT on ConsistENcy, SatisfaCtion and Tolerability of TrEatment in the Real World (AAN 2025) - "Meaningful pain relief and restoration of function occurred within 2 hours for the majority of attacks with high levels of population consistency from attack to attack."

Clinical • Observational data • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain